Biosimilars Forum的动态

?? Did you know? Biosimilars can provide an average cost savings of 30% compared to branded biologics! ?? As the healthcare industry continues to focus on value and accessibility, biosimilars are emerging as a game-changer. By offering safe, effective, and more affordable alternatives to branded biologics, biosimilars are making critical therapies more accessible to patients worldwide. These cost savings don’t just benefit patients—they also create opportunities for healthcare systems, insurers, and providers to reduce overall healthcare spending and reinvest in innovative treatments. With rising healthcare costs, it’s time for us all to explore the impact that biosimilars can have on both affordability and patient access. #Biosimilars #HealthcareInnovation #PatientAccess #AffordableHealthcare

The biologics market is estimated at US$447.0 billion in 2023 and is projected to grow at a CAGR of 8.5% during the forecast period 2024-2034. Access our new #Pharma report by downloading it here: https://ow.ly/YwkT50Sv9S4

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health? is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/gdMTRZfK #TeamCVS

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health? is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/eRW6Rcix #TeamCVS

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health? is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/eX9EbtsH #TeamCVS

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health? is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/gSVtVZi2 #TeamCVS

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health? is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/eSTmb32H #TeamCVS

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health? is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/dgq4pJN9 #TeamCVS

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health? is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/dUYk4wrE #TeamCVS

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health? is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/eNnYXZHg #TeamCVS